查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乳腺癌液體活檢市場規模、份額和趨勢分析報告：循環生物標誌物（循環腫瘤細胞、循環無細胞 DNA、細胞外囊泡），按應用、地區、細分市場預測，2022-2030 年
市場調查報告書
商品編碼
1170885

乳腺癌液體活檢市場規模、份額和趨勢分析報告：循環生物標誌物（循環腫瘤細胞、循環無細胞 DNA、細胞外囊泡），按應用、地區、細分市場預測，2022-2030 年

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), By Application, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

乳腺癌液體活檢市場增長及趨勢

據Grandview Research最新報告顯示，2022-2030年全球乳腺癌液體活檢市場預計將以22.7%的複合年增長率增長，到2030年將達到17億美元。這種增長的背後是對非侵入性技術的日益偏好、早期診斷和治療意識的提高以及乳腺癌患病率的增加。例如，據世界衛生組織稱，到 2020 年，乳腺癌將奪去 685,000 名婦女的生命，並影響全球 230 萬名婦女。液體活檢已被提議作為乳腺癌早期檢測的突破性技術，促進其採用並刺激增長。

隨著乳腺癌發病率的增加，人們迫切需要提供合適的診斷工具，以實現癌症的早期發現和早期治療。為了滿足日益增長的需求，診斷試劑領域的研究和開發正在加緊進行。例如，2022 年 6 月，BioFluidica 研究結果表明，HER2 陽性乳腺癌患者在接受 HER2 定向定制治療時具有成功率。隨著相關領域的發展，液體活檢的臨床相關性越來越廣為人知。進一步的介入性臨床試驗和構建適當結合循環生物標誌物的算法對於廣泛採用這些技術是必要的。

正在進行的心血管生物標誌物研究中的技術突破導致了用於識別非血液惡性腫瘤的微創技術的發展。與傳統的腫瘤活檢相比，液體活檢被認為是實時患者監測的一種有前途的選擇。例如，2022 年 4 月，Epic Science 將 DefineMBC 添加到其 CLIA 實驗室組合中，DefineMBC 是一種基於液體活檢技術的血液檢測，用於診斷轉移性乳腺癌。

此外，市場上的主要參與者正專注於擴展和推出可用於廣泛應用的產品。例如，2022 年 6 月，NeoGenomics 的子公司 Inivata Limited 宣布了 RaDaR 分析的新數據，用於分析人類表皮生長因子受體 2 (HER2) 陰性高危患者的微小殘留病 (MRD) 和復發。宣布。

乳腺癌液體活檢市場報告亮點

2021年，循環腫瘤細胞領域將佔據壓倒性的收入份額，因為CTC在癌症檢測中的高效性和準確性

由於在早期癌症診斷中越來越多地採用液體活檢以及對提供有效治療的需求不斷增長，預計早期檢測部分在預測期內將以最快的複合年增長率增長。

治療選擇是 2021 年創收最高的部分，因為有許多產品可以幫助治療選擇

由於患病率增加、醫療基礎設施改善和人口增長，亞太地區預計在預測期內增長最快。

目錄

第一章 調查方法和範圍

  • 市場細分
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • 次要信息
    • 初步調查
    • 初步調查詳情
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：國家——使用自下而上的方法進行智能市場估算
  • 全球市場：複合年增長率計算
  • 調查假設
  • 二級信息列表
  • 主要信息列表
  • 目的
  • 縮略語表

第二章執行摘要

  • 市場概況

3 乳腺癌液體活檢市場變量、趨勢和範圍

  • 乳腺癌液體活檢市場譜系展望
    • 母公司市場展望
    • 輔助市場展望 - 體外診斷 (Ivd) 市場
  • 繪製滲透率和增長前景
  • 市場動態
  • 市場驅動力分析
    • 乳腺癌患病率增加
    • 在癌症診斷中越來越多地採用液體活檢
    • 需要早期診斷和治療
  • 市場約束因素分析
    • 與乳腺癌液體活檢相關的高成本
    • 監管和報銷障礙
  • 按因素（政治和法律、經濟、技術）的 SWOT 分析
  • 波特五力分析

第 4 章循環生物標誌物的乳腺癌液體活檢市場細分分析，2018-2030（百萬美元）

  • 乳腺癌液體活檢市場：循環生物標誌物的變化分析
    • 循環腫瘤細胞 (Ctcs)
    • 循環無細胞 DNA (Cfdna)
    • 細胞外囊泡 (Ev)
    • 其他循環生物標誌物

第 5 章乳腺癌液體活檢市場-細分分析，按應用，2018-2030 年（百萬美元）

  • 乳腺癌液體活檢市場：應用差異分析
    • 早期檢測/篩查
    • 診斷
    • 治療選擇
    • 監控

6. 2018-2030 年按地區分列的乳腺癌液體活檢市場細分分析（百萬美元）

  • 乳腺癌液體活檢市場：區域差異分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
      • 2018-2030 年意大利乳腺癌液體活檢市場（百萬美元）
    • 西班牙
      • 2018-2030 年西班牙乳腺癌液體活檢市場（百萬美元）
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
      • 2018-2030 年澳大利亞乳腺癌液體活檢市場（百萬美元）
    • 韓國
      • 2018-2030 年韓國乳腺癌液體活檢市場（百萬美元）
  • 拉丁美洲
    • 拉丁美洲乳腺癌液體活檢市場，2018-2030（百萬美元）
    • 巴西
      • 2018-2030 年巴西乳腺癌液體活檢市場（百萬美元）
    • 墨西哥
      • 2018-2030 年墨西哥乳腺癌液體活檢市場（百萬美元）
    • 阿根廷
      • 阿根廷乳腺癌液體活檢市場，2018-2030（百萬美元）
  • 馬雷
    • Mea 乳腺癌液體活檢市場，2018-2030（百萬美元）
    • 南非
      • 2018-2030 年南非乳腺癌液體活檢市場（百萬美元）
    • 沙特阿拉伯
      • 沙特阿拉伯乳腺癌液體活檢市場，2018-2030（百萬美元）
    • 阿拉伯聯合酋長國
      • 阿拉伯聯合酋長國乳腺癌液體活檢市場，2018-2030 年（百萬美元）

7 乳腺癌液體活檢市場：競爭分析

  • 主要市場進入者的最新發展和影響分析
    • 安索夫矩陣
    • 重大交易及戰略聯盟分析
      • 市場拓展
      • 產品發布會
      • 獲得
      • 夥伴關係和協作
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
    • 主要客戶
    • 2021 年主要參與者的市場份額分析
  • 上市公司
    • 公司市場分析
    • 熱圖分析
    • 區域網絡圖
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 民營企業
    • 主要初創企業名單
    • 熱圖分析
    • 區域網絡圖

第八章公司簡介

  • The Menarini Group
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • NeoGenomics Laboratories
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • F. Hoffmann-La Roche Ltd.,
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Myriad Genetics, Inc.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Thermo Fisher Scientific, Inc.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • QIAGEN
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Biocept, Inc.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Sysmex Corporation
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Fluxion Biosciences, Inc.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Epic Sciences, Inc.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
Product Code: GVR-4-68039-991-9

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

  • In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer
  • The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment
  • Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection
  • Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Secondary Sources
    • 1.3.3 Primary Research
    • 1.3.4 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country - Wise Market Estimation Using Bottom - Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Breast Cancer Liquid Biopsy Market Variables, Trends, & Scope

  • 3.1 Breast Cancer Liquid Biopsy Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (Ivd) Market
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Market Dynamics
  • 3.4 Market Driver Analysis
    • 3.4.1 Increasing Prevalence Of Breast Cancer
    • 3.4.2 Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
    • 3.4.3 Need To Provide Early Diagnosis And Treatment
  • 3.5 Market Restraint Analysis
    • 3.5.1 High Cost Associated With Breast Cancer Liquid Biopsy Tests
    • 3.5.2 Regulatory & Reimbursement Hurdles
  • 3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.7 Porter's Five Forces Analysis

Chapter 4 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Circulating Biomarkers, 2018 - 2030 (USD Million)

  • 4.1 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
    • 4.1.1 Circulating Tumor Cells (Ctcs)
      • 4.1.1.1 Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.2 Circulating Cell - Free Dna (Cfdna)
      • 4.1.2.1 Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.3 Extracellular Vesicles (Evs)
      • 4.1.3.1 Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.4 Other Circulating Biomarkers
      • 4.1.4.1 Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Breast Cancer Liquid Biopsy Market: Application Movement Analysis
    • 5.1.1 Early Detection/Screening
      • 5.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Diagnosis
      • 5.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.3 Treatment Selection
      • 5.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.4 Monitoring
      • 5.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Breast Cancer Liquid Biopsy Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 6.1 Breast Cancer Liquid Biopsy Market: Regional Movement Analysis
  • 6.2 North America
    • 6.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Italy Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Spain Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.4 Australia
      • 6.4.4.1 Australia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.4.5 South Korea
      • 6.4.5.1 South Korea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.3 Argentina
      • 6.5.4.1 Argentina Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.6 Mea
    • 6.6.1 Mea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Saudi Arabia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 UAE Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 7 Breast Cancer Liquid Biopsy Market: Competitive Analysis

  • 7.1 Recent developments and impact analysis, by key market participants
    • 7.1.1 Ansoff Matrix
    • 7.1.2 Major Deals And Strategic Alliances Analysis
      • 7.1.2.1 Market Expansion
      • 7.1.2.2 Product Launch
      • 7.1.2.3 Acquisition
      • 7.1.2.4 Partnerships And Collaborations
  • 7.2 Company Categorization
    • 7.2.1 Innovators
    • 7.2.2 Market Leaders
  • 7.3 Vendor Landscape
    • 7.3.1 List Of Key Distributors And Channel Partners
    • 7.3.2 Key Customers
    • 7.3.3 Key Company Market Share Analysis, 2021
  • 7.4 Public Companies
    • 7.4.1 Company Market Position Analysis
    • 7.4.2 Heat Map Analysis
    • 7.4.3 Regional Network Map
    • 7.4.4 Competitive Dashboard Analysis
      • 7.4.4.1 Market Differentiators
  • 7.5 Private Companies
    • 7.5.1 List Of Key Emerging Companies
    • 7.5.2 Heat Map Analysis
    • 7.5.3 Regional Network Map

Chapter 8 Company Profiles

  • 8.1 The Menarini Group
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 NeoGenomics Laboratories
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 F. Hoffmann - La Roche Ltd.,
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.2 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Myriad Genetics, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Thermo Fisher Scientific, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
    • 8.5.4 Strategic Initiatives
  • 8.6 QIAGEN
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.2 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 Biocept, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 Sysmex Corporation
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.9 Fluxion Biosciences, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 Epic Sciences, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviations
  • TABLE 3 Regulatory framework
  • TABLE 4 Global breast cancer liquid biopsy market, by region, 2018 - 2030 (USD Million)
  • TABLE 5 Global breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 6 Global breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 7 North America breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 8 North America breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 9 North America breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 12 Canada breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 13 Canada breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 14 Europe breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 15 Europe breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 16 Europe breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 17 U.K. breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 18 U.K. breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 19 Germany breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 20 Germany breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 21 Spain breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 22 Spain breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 23 France breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 24 France breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 25 Italy breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 26 Italy breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 27 Asia Pacific breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 28 Asia Pacific breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 29 Asia Pacific breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 30 Japan breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 31 Japan breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 32 China breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 33 China breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 34 India market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 35 India breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 36 Australia market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 37 Australia breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 38 South Korea market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 39 South Korea breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 40 South Korea breast cancer liquid biopsy market, by product circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 41 Latin America breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 42 Latin America breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 43 Latin America breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Brazil breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 45 Brazil breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 46 Mexico breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 47 Mexico breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 48 Argentina breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 49 Argentina breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 50 MEA breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 51 MEA breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 52 MEA breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 53 South Africa breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 54 South Africa breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 55 Saudi Arabia breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 56 Saudi Arabia breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 57 UAE breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 58 UAE breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Breast cancer liquid biopsy market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value - chain - based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Breast cancer liquid biopsy market snapshot
  • FIG. 10 Penetration and growth prospect mapping for application, 2021 (USD Million)
  • FIG. 11 Market Dynamics
  • FIG. 12 Breast cancer liquid biopsy market driver impact
  • FIG. 13 Enzymes in the diagnosis of diseases
  • FIG. 14 Common applications of enzymes in pathology
  • FIG. 15 Breast cancer liquid biopsy market restraint impact
  • FIG. 16 Porter's five forces analysis
  • FIG. 17 Breast cancer liquid biopsy market: Circulating biomarkers outlook and key takeaways
  • FIG. 18 Circulating tumor Cells (CTCs) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 19 Circulating cell - free DNA (cfDNA) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 20 Extracellular Vesicles (EVs) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Others circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Breast cancer liquid biopsy market: Application outlook and key takeaways
  • FIG. 23 Breast cancer liquid biopsy market: Application movement analysis
  • FIG. 24 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 25 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Monitoring market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 28 Breast cancer liquid biopsy Market: Regional outlook and key takeaways
  • FIG. 29 Breast cancer liquid biopsy: Regional movement analysis
  • FIG. 30 North America
  • FIG. 31 North America. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 U.S.
  • FIG. 33 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 34 Canada
  • FIG. 35 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 Europe
  • FIG. 37 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 38 UK
  • FIG. 39 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 40 Germany
  • FIG. 41 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 France
  • FIG. 43 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Spain
  • FIG. 45 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 Italy
  • FIG. 47 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Asia Pacific
  • FIG. 49 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Japan
  • FIG. 51 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 52 China
  • FIG. 53 China. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 54 India
  • FIG. 55 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 56 Australia
  • FIG. 57 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 South Korea
  • FIG. 59 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 Latin America
  • FIG. 61 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Brazil
  • FIG. 63 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Mexico
  • FIG. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 Argentina
  • FIG. 67 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 MEA
  • FIG. 69 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 South Africa
  • FIG. 71 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Saudi Arabia
  • FIG. 73 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 UAE
  • FIG. 75 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Ansoff Matrix
  • FIG. 77 Strategy mapping
  • FIG. 78 Company market share analysis, 2021
  • FIG. 79 Heat map analysis
  • FIG. 80 Market differentiators
  • FIG. 81 Heat map analysis
  • FIG. 82 Regional network map